中华皮肤科杂志 ›› 2017, Vol. 50 ›› Issue (11): 777-783.doi: 10.3760/cma.j.issn.0412-4030.2017.11.001
• 专家论坛 • 下一篇
姚志荣
收稿日期:2017-04-13
修回日期:2017-09-20
发布日期:2017-11-02
通讯作者:
姚志荣
E-mail:dermatology.yao@sohu.com
Yao Zhirong
Received:2017-04-13
Revised:2017-09-20
Published:2017-11-02
摘要： 儿童皮肤病学既是皮肤病学的一部分，又是一个相对完整独立的体系。儿童皮肤病有其独特性，主要表现在儿童的皮肤组织结构、生理代谢、疾病谱及其对局部和系统用药的代谢特点均与成人有较大的差异。但儿童皮肤病又是我们人类皮肤某一个阶段的异常，有些表现持续至成年以后，有些甚至在成年阶段进一步演化，因此我们又需要用整体的观念去看待儿童皮肤病的发生、发展和演化，而不能将两个阶段完全割裂开来。现代医学技术特别是分子生物学与免疫学的发展，带来了皮肤病学多方面认识的革命，毫无疑问，也影响了儿童皮肤病学的发展，尤其体现在遗传性皮肤病、变态反应性皮肤病、感染性皮肤病、肿瘤性皮肤病、激光医学与美容等多个方面。本文主要从这些方面进行回顾和展望……
姚志荣. 儿童皮肤病学发展现状与未来[J]. 中华皮肤科杂志, 2017,50(11):777-783. doi:10.3760/cma.j.issn.0412-4030.2017.11.001
Yao Zhirong. Development of pediatric dermatology: present status and future prospects[J]. Chinese Journal of Dermatology, 2017, 50(11): 777-783.doi:10.3760/cma.j.issn.0412-4030.2017.11.001
| ［1］ | Lin Z, Li S, Feng C, et al. Stabilizing mutations of KLHL24 ubiquitin ligase cause loss of keratin 14 and human skin fragility［J］. Nat Genet, 2016, 48（12）: 1508⁃1516. DOI: 10.1038/ng.3701. |
| ［2］ | Lin Z, Zhao J, Nitoiu D, et al. Loss⁃of⁃function mutations in CAST cause peeling skin, leukonychia, acral punctate keratoses, cheilitis, and knuckle pads［J］. Am J Hum Genet, 2015, 96（3）: 440⁃447. DOI: 10.1016/j.ajhg.2014.12.026. |
| ［3］ | Liu Y, Gao M, Lv YM, et al. Confirmation by exome sequencing of the pathogenic role of NCSTN mutations in acne inversa （hidradenitis suppurativa）［J］. J Invest Dermatol, 2011, 131（7）: 1570⁃1572. DOI: 10.1038/jid.2011.62. |
| ［4］ | Ni C, Yan M, Zhang J, et al. A novel mutation in TRPV3 gene causes atypical familial Olmsted syndrome［J］. Sci Rep, 2016, 6: 21815. DOI: 10.1038/srep21815. |
| ［5］ | Li M, Cheng R, Liang J, et al. Mutations in POFUT1, encoding protein O⁃fucosyltransferase 1, cause generalized Dowling⁃Degos disease［J］. Am J Hum Genet, 2013, 92（6）: 895⁃903. DOI: 10.1016/j.ajhg.2013.04.022. |
| ［6］ | Takeichi T, Akiyama M. Inherited ichthyosis: non⁃syndromic forms［J］. J Dermatol, 2016, 43（3）: 242⁃251. DOI: 10.1111/1346⁃8138.13243. |
| ［7］ | Tang L, Liang J, Wang W, et al. A novel mutation in MBTPS2 causes a broad phenotypic spectrum of ichthyosis follicularis, atrichia, and photophobia syndrome in a large Chinese family［J］. J Am Acad Dermatol, 2011, 64（4）: 716⁃722. DOI: 10.1016/j.jaad.2010.02.045. |
| ［8］ | Zhang J, Wang Y, Cheng R, et al. Novel MBTPS2 missense mutation causes a keratosis follicularis spinulosa decalvans phenotype: mutation update and review of the literature［J］. Clin Exp Dermatol, 2016, 41（7）: 757⁃760. DOI: 10.1111/ced.12889. |
| ［9］ | Li M, Wang J, Zhang J, et al. Genome⁃wide linkage and exome sequencing analyses identify an initiation codon mutation of KRT5 in a unique Chinese family with generalized Dowling⁃Degos disease［J］. Br J Dermatol, 2016, 174（3）: 663⁃666. DOI: 10.1111/bjd.14178. |
| ［10］ | Reisenauer AK, Wordingham SV, York J, et al. Heterozygous frameshift mutation in keratin 5 in a family with Galli⁃Galli disease［J］. Br J Dermatol, 2014, 170（6）: 1362⁃1365. DOI: 10.1111/bjd.12813. |
| ［11］ | Zhang J, Yan M, Liang J, et al. A novel KRT5 mutation associated with generalized severe epidermolysis bullosa simplex in a 2⁃year⁃old Chinese boy［J］. Exp Ther Med, 2016, 12（5）: 2823⁃2826. DOI: 10.3892/etm.2016.3717. |
| ［12］ | Li M, Han J, Lu Z, et al. Prevalent and rare mutations in IL⁃36RN gene in Chinese patients with generalized pustular psoriasis and psoriasis vulgaris［J］. J Invest Dermatol, 2013, 133（11）: 2637⁃2639. DOI: 10.1038/jid.2013.267. |
| ［13］ | Biggs CM, Lu HY, Turvey SE. Monogenic immune disorders and severe atopic disease［J］. Nat Genet, 2017, 49（8）: 1162⁃1163. DOI: 10.1038/ng.3925. |
| ［14］ | Cheng WL, Hsiao CH, Tseng HW, et al. Noninvasive prenatal diagnosis［J］. Taiwan J Obstet Gynecol, 2015, 54（4）: 343⁃349. DOI: 10.1016/j.tjog.2015.05.002. |
| ［15］ | Mavilio F, Pellegrini G, Ferrari S, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells［J］. Nat Med, 2006, 12（12）: 1397⁃1402. DOI: 10.1038/nm1504. |
| ［16］ | Murauer EM, Koller U, Pellegrini G, et al. Advances in gene/cell therapy in epidermolysis bullosa［J］. Keio J Med, 2015, 64（2）: 21⁃25. DOI: 10.2302/kjm.2014⁃0013⁃RE. |
| ［17］ | Cogan J, Weinstein J, Wang X, et al. Aminoglycosides restore full⁃length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa［J］. Mol Ther, 2014, 22（10）:1741⁃1752. DOI: 10.1038/mt.2014.140. |
| ［18］ | Atanasova VS, Jiang Q, Prisco M, et al. Amlexanox enhances premature termination codon read⁃through in COL7A1 and of full length type Ⅶ collagen: potential therapy for recessive dystrophic epidermolysis bullosa［J］. J Invest Dermatol, 2017, 137（9）: 1842⁃1849. DOI: 10.1016/j.jid.2017.05.011. |
| ［19］ | Guo Y, Li P, Tang J, et al. Prevalence of atopic dermatitis in Chinese children aged 1⁃7 ys［J］. Sci Rep, 2016, 6: 29751. DOI: 10.1038/srep29751. |
| ［20］ | Malajian D, Guttman⁃Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis［J］. Cytokine, 2015, 73（2）: 311⁃318. DOI: 10.1016/j.cyto.2014.11.023. |
| ［21］ | Zhang H, Guo Y, Wang W, et al. Mutations in the filaggrin gene in Han Chinese patients with atopic dermatitis［J］. Allergy, 2011, 66（3）: 420⁃427. DOI: 10.1111/j.1398⁃9995.2010.02493.x. |
| ［22］ | Zhang H, Guo Y, Wang W, et al. Associations of FLG mutations between ichthyosis vulgaris and atopic dermatitis in Han Chinese［J］. Allergy, 2011, 66（9）: 1253⁃1254. DOI: 10.1111/j.1398⁃9995.2011.02597.x. |
| ［23］ | Li M, Liu Q, Liu J, et al. Mutations analysis in filaggrin gene in northern China patients with atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2013, 27（2）: 169⁃174. DOI: 10.1111/j.1468⁃3083.2011.04435.x. |
| ［24］ | Weidinger S, Novak N. Atopic dermatitis［J］. Lancet, 2016, 387（10023）: 1109⁃1122. DOI: 10.1016/S0140⁃6736（15）00149⁃X. |
| ［25］ | Novak N, Valenta R, Bohle B, et al. FcepsilonRI engagement of Langerhans cell⁃like dendritic cells and inflammatory dendritic epidermal cell⁃like dendritic cells induces chemotactic signals and different T⁃cell phenotypes in vitro［J］. J Allergy Clin Immunol, 2004, 113（5）: 949⁃957. DOI: 10.1016/j.jaci.2004.02. 005. |
| ［26］ | Feingold KR. The adverse effect of IFN gamma on stratum corneum structure and function in psoriasis and atopic dermatitis［J］. J Invest Dermatol, 2014, 134（3）: 597⁃600. DOI: 10.1038/jid.2013.440. |
| ［27］ | Nograles KE, Suárez⁃Fariñas M, Shemer A, et al. Atopic dermatitis keratinocytes exhibit normal Th17 cytokine responses［J］. J Allergy Clin Immunol, 2010, 125（3）: 744⁃746, 746. e1⁃746.e2. DOI: 10.1016/j.jaci.2009.12.934. |
| ［28］ | Gutowska⁃Owsiak D, Schaupp AL, Salimi M, et al. Interleukin⁃22 downregulates filaggrin and affects of profilaggrin processing enzymes［J］. Br J Dermatol, 2011, 165（3）: 492⁃498. DOI: 10.1111/j.1365⁃2133.2011.10400.x. |
| ［29］ | Czarnowicki T, Esaki H, Gonzalez J, et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen （CLA）（+） TH2/TH1 cell imbalance, whereas adults acquire CLA（+） TH22/TC22 cell subsets［J］. J Allergy Clin Immunol, 2015, 136（4）: 941⁃951.e3. DOI: 10.1016/j.jaci.2015.05.049. |
| ［30］ | Doherty TA, Broide DH. Group 2 innate lymphoid cells: new players in human allergic diseases［J］. J Investig Allergol Clin Immunol, 2015, 25（1）: 1⁃11; quiz 2p following 11. |
| ［31］ | Maggi L, Montaini G, Mazzoni A, et al. Human circulating group 2 innate lymphoid cells can express CD154 and promote IgE production［J］. J Allergy Clin Immunol, 2017, 139（3）: 964⁃976.e4. DOI: 10.1016/j.jaci.2016.06.032. |
| ［32］ | Vukmanovic⁃Stejic M, McQuaid A, Birch KE, et al. Relative impact of CD4+CD25+ regulatory T cells and tacrolimus on inhibition of T⁃cell proliferation in patients with atopic dermatitis［J］. Br J Dermatol, 2005, 153: 750⁃757. DOI: 10.1111/j.1365⁃2133.2005.06675.x. |
| ［33］ | Verhagen J, Akdis M, Traidl⁃Hoffmann C, et al. Absence of T⁃regulatory cell and function in atopic dermatitis skin［J］. J Allergy Clin Immunol, 2006,117（1）:176⁃183. DOI: 10.1016/j.jaci.2005.10.040. |
| ［34］ | Kim JH, Bae HC, Ko NY, et al. Thymic stromal lymphopoietin downregulates filaggrin by signal transducer and activator of transcription 3 （STAT3） and extracellular signal⁃regulated kinase （ERK） phosphorylation in keratinocytes［J］. J Allergy Clin Immunol, 2015,136（1）:205⁃208.e9. DOI: 10.1016/j.jaci.2015.04.026. |
| ［35］ | Dybboe R, Bandier J, Skov L, et al. The role of the skin microbiome in atopic dermatitis: a systematic review［J］. Br J Dermatol, 2017, DOI: 10.1111/bjd.15390. |
| ［36］ | Brenninkmeijer EE, Schram ME, Leeflang MM, et al. Diagnostic criteria for atopic dermatitis: a systematic review［J］. Br J Dermatol, 2008, 158（4）: 754⁃765. DOI: 10.1111/j.1365-2133. 2007.08412.x. |
| ［37］ | Cheng R, Guo Y, Huang L, et al. Current status in diagnosis of atopic dermatitis in China［J］. Allergy, 2017, 72（9）: 1277⁃1278. DOI: 10.1111/all.13149. |
| ［38］ | Notaro ER, Sidbury R. Systemic agents for severe atopic dermatitis in children［J］. Pediatric Drugs, 2015, 17（6）: 449⁃457. DOI: 10.1007/s40272⁃015⁃0150⁃4. |
| ［39］ | Plötz SG, Wiesender M, Todorova A, et al. What is new in atopic dermatitis/eczema?［J］. Expert Opin Emerg Drugs, 2014, 19（4）: 441⁃458. DOI: 10.1517/14728214.2014.953927. |
| ［40］ | Bae JM, Choi YY, Park CO, et al. Efficacy of allergen⁃specific immunotherapy for atopic dermatitis: a systematic review and meta⁃analysis of randomized controlled trials［J］. J Allergy Clin Immunol, 2013, 132（1）: 110⁃117. DOI: 10.1016/j.jaci.2013.02. 044. |
| ［41］ | Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5⁃year randomized trial［J］. Pediatrics, 2015, 135（4）: 597⁃606. DOI: 10.1542/peds.2014⁃1990. |
| ［42］ | Ciaravino V, Coronado D, Lanphear C, et al. 2⁃Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis［J］. J Dermatol Sci, 2017, 87（2）: 116⁃122. DOI: 10.1016/j.jdermsci.2017.03.020. |
| ［43］ | Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate⁃to⁃severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo⁃controlled, dose⁃ranging phase 2b trial［J］. Lancet, 2016, 387（10013）: 40⁃52. DOI: 10.1016/S0140⁃6736（15）00388⁃8. |
| ［44］ | Tsianakas A, Ständer S. Dupilumab: a milestone in the treatment of atopic dermatitis［J］. Lancet, 2016, 387（10013）: 4⁃5. DOI: 10.1016/S0140⁃6736（15）00389⁃X. |
| ［45］ | Li H, Li C, Zhang H, et al. Effects of lidocaine on regulatory T cells in atopic dermatitis［J］. J Allergy Clin Immunol, 2016, 137（2）: 613⁃617. e5. DOI: 10.1016/j.jaci.2015.07.039. |
| ［46］ | Wawrzyniak P, Akdis CA, Finkelman FD, et al. Advances and highlights in mechanisms of allergic disease in 2015［J］. J Allergy Clin Immunol, 2016, 137（6）: 1681⁃1696. DOI: 10.1016/j.jaci. 2016.02.010. |
| ［47］ | Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention［J］. J Allergy Clin Immunol, 2014, 134（4）: 818⁃823. DOI: 10.1016/j.jaci.2014.08.005. |
| ［48］ | Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis［J］. J Allergy Clin Immunol, 2014, 134（4）: 824⁃830. e6. DOI: 10.1016/j.jaci.2014.07.060. |
| ［49］ | Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2014［J］. J Allergy Clin Immunol, 2015, 135（2）: 357⁃367. DOI: 10.1016/j.jaci.2014.12.1906. |
| ［50］ | Vestita M, Filoni A, Congedo M, et al. Vitamin D and atopic dermatitis in childhood［J］. J Immunol Res, 2015, 2015: 257879. DOI: 10.1155/2015/257879. |
| ［51］ | Penders J, Gerhold K, Stobberingh EE, et al. Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood［J］. J Allergy Clin Immunol, 2013, 132（3）: 601⁃607.e8. DOI: 10.1016/j.jaci.2013.05.043. |
| ［52］ | Fyhrquist N, Ruokolainen L, Suomalainen A, et al. Acinetobacter species in the skin microbiota protect against allergic sensitization and inflammation［J］. J Allergy Clin Immunol, 2014, 134（6）: 1301⁃1309.e11. DOI: 10.1016/j.jaci.2014.07.059. |
| ［53］ | Tao J, He XY, Shi Y, et al. Epidemiology of 45,616 suspect cases of hand, foot and mouth disease in Chongqing, China, 2011⁃2015［J］. Sci Rep, 2017, 7: 45630. DOI: 10.1038/srep45630. |
| ［54］ | Feng X, Guan W, Guo Y, et al. A novel recombinant lineage's contribution to the outbreak of coxsackievirus A6⁃associated hand, foot and mouth disease in Shanghai, China, 2012⁃2013［J］. Sci Rep, 2015, 5: 11700. DOI: 10.1038/srep11700. |
| ［55］ | Weinberg JM, Tyring SK. Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus［J］. J Drugs Dermatol, 2010, 9（10）: 1198⁃1204. |
| ［56］ | Bangert S, Levy M, Hebert AA. Bacterial resistance and impetigo treatment trends: a review［J］. Pediatr Dermatol, 2012, 29（3）: 243⁃248. DOI: 10.1111/j.1525⁃1470.2011.01700.x. |
| ［57］ | Silverberg N, Block S. Uncomplicated skin and skin structure infections in children: diagnosis and current treatment options in the United States［J］. Clin Pediatr （Phila）, 2008, 47（3）: 211⁃219. DOI: 10.1177/0009922807307186. |
| ［58］ | Hartman⁃Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment［J］. Am Fam Physician, 2014, 90（4）: 229⁃235. |
| ［59］ | 刘元香, 徐子刚. EB病毒感染相关皮肤疾病的研究进展［J］. 中华实用儿科临床杂志, 2016, 31（22）: 1757⁃1760. DOI: 10.3760/cma.j.issn.2095⁃428X.2016.22.020. |
| ［60］ | Léauté⁃Labrèze C, de la Roque E D, Hubiche T, et al. Propranolol for severe hemangiomas of infancy［J］. N Engl J Med, 2008, 358（24）: 2649⁃2651. DOI: 10.1056/NEJMc0708819. |
| ［61］ | Léauté⁃Labrèze C, Hoeger P, Mazereeuw⁃Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma［J］. N Engl J Med, 2015, 372（8）: 735⁃746. DOI: 10.1056/NEJMoa1404710. |
| ［62］ | Iacobas I, Burrows PE, Adams DM, et al. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation［J］. Pediatr Blood Cancer, 2011, 57（2）: 321⁃323. DOI: 10.1002/pbc.23098. |
| ［63］ | Canpolat M, Per H, Gumus H, et al. Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86［J］. Childs Nerv Syst, 2014, 30（2）: 227⁃240. DOI: 10.1007/s00381⁃013⁃2185⁃6. |
| ［64］ | Wang S, Liu Y, Wei J, et al. Tuberous sclerosis complex in 29 children: clinical and genetic analysis and facial angiofibroma responses to topical sirolimus［J］. Pediatr Dermatol, 2017, 34（5）: 572⁃577. DOI: 10.1111/pde.13204. |
| ［65］ | Gao L, Nadora DM, Phan S, et al. Topical axitinib suppresses angiogenesis pathways induced by pulsed dye laser［J］. Br J Dermatol, 2015, 172（3）: 669⁃676. DOI: 10.1111/bjd.13439. |
| ［66］ | Brightman LA, Geronemus RG, Reddy KK. Laser treatment of port⁃wine stains［J］. Clin Cosmet Investig Dermatol, 2015, 8: 27⁃33. DOI: 10.2147/CCID.S53118. |
| ［67］ | Shah VV, Bray FN, Aldahan AS, et al. Lasers and nevus of Ota: a comprehensive review［J］. Lasers Med Sci, 2016, 31（1）: 179⁃185. DOI: 10.1007/s10103⁃015⁃1834⁃2. |
| ［68］ | Chesnut C, Diehl J, Lask G. Treatment of nevus of ota with a picosecond 755⁃nm alexandrite laser［J］. Dermatol Surg, 2015, 41（4）: 508⁃510. DOI: 10.1097/DSS.0000000000000326. |
| No related articles found! |
|
